Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

General Information and Reorganization Transaction - Additional Information (Details)

General Information and Reorganization Transaction - Additional Information (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 07, 2024	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Disclosure of reclassifications or changes in presentation [line items]
Cash			$ 3,589,244	$ 9,352,538
Current liabilities			168,849	908,401
Net decrease in cash			(5,763,294)	9,330,782	$ 4,135
Accumulated deficit			18,527,997	11,794,460
Cash flows used in operating activities			$ (6,247,016)	$ (4,179,767)	(809,070)
Number of shares issued			2,573,903	1,554,709
Net proceeds			$ 234	$ 13,654,347	$ 519,613
At-the-Market Offering \| Events After Reporting Period
Disclosure of reclassifications or changes in presentation [line items]
Number of shares issued	391,017	391,017
Average price of shares	$ 1.9931	$ 1.9931
Net proceeds	$ 754,511	$ 754,511
Virax Biolabs Group Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Sep. 02, 2021
Virax Biolabs (UK) Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Aug. 19, 2021
Virax Biolabs HKCo Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Apr. 14, 2020
Virax Immune T- Cell Medical Device Company Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Jan. 16, 2017
Virax Biolabs Pte. Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			May 04, 2013
Third Party Shareholders
Disclosure of reclassifications or changes in presentation [line items]
Percentage of capital owned			4.35%
Logico Bioproducts Corp.
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Jan. 21, 2011
Shanghai Xitu Consulting Co., Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Oct. 27, 2017
Virax Biolabs USA Management, Inc.
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Aug. 01, 2022
Virax Biolabs Group Holdings Ltd
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Feb. 22, 2023
Virax Biolabs FZ-LLC
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Apr. 18, 2023
Virax Biolabs Trading B.V.
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Aug. 04, 2023
Virax Biolabs UK Operating Limited
Disclosure of reclassifications or changes in presentation [line items]
Date of incoporation			Nov. 07, 2023